Tag
Rapid and excessive expansion of ciltacabtagene autoleucel (cilta-cel) CAR T-cells associates with delayed neurotoxicity in relapsed/refractory multiple myeloma, with absolute lymphocyte count serving as a practical biomarker to guide early
This study identifies immunoglobulin heavy chain constant domain-derived peptides as promising TCR therapy targets in multiple myeloma, demonstrating selective cytotoxicity and potential to preserve humoral immunity.
This study provides a comprehensive single-cell immune atlas of multiple myeloma, revealing dynamic tumor microenvironment ecotypes linked to disease progression, immune dysfunction, and treatment response, offering new avenues for precisio
BCMA-targeted CAR T-cell therapy demonstrates substantial efficacy and an acceptable safety profile as a salvage option for relapsed/refractory multiple myeloma patients after failure of prior anti-GPRC5D CAR T-cell treatments.
This article explores the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a promising targeted therapy that degrades oncogenic NSD2 in t(4;14) multiple myeloma, reversing malignant epigenomic programs and improving disease outcomes i
Soluble BCMA levels in newly diagnosed multiple myeloma patients reveal distinct tumor phenotypes and predict prognosis more strongly than tumor volume, enabling improved risk stratification and clinical decision-making.
Maintenance therapies—lenalidomide, thalidomide, and bortezomib—significantly improve survival after autologous stem cell transplant for multiple myeloma, regardless of initial response status, based on a large global registry analysis.
PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.
This phase II study evaluates the all-oral ixazomib-pomalidomide-dexamethasone regimen in triple-class exposed relapsed/refractory multiple myeloma patients, demonstrating promising efficacy and manageable safety in an elderly and high-risk
This study develops a high-content ex vivo assay of T cell dynamics to predict multiple myeloma patient response to bispecific T cell engager therapies, offering a novel functional biomarker for therapy stratification.
Single-cell transcriptomic profiling of ide-cel CAR-T products reveals that intrinsic NF-κB signaling in CD4 CAR-T cells correlates with durable remission in relapsed/refractory multiple myeloma, marking T-cell fitness and potential therape
Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and saf
Circulating tumor cells (CTCs) enhance the IMS-IMWG 2025 genomic staging by identifying a disseminated high-risk phenotype in newly diagnosed multiple myeloma, improving prognostic stratification and enabling minimally invasive disease moni
Arlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including pr
CT0590, a novel allogeneic BCMA CAR T-cell therapy armored with NKG2A to resist host NK cell attacks, demonstrates promising safety and efficacy in relapsed/refractory multiple myeloma and plasma cell leukemia, addressing key transplant rej
Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.
The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients
Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.
USP8 regulates proteostasis in B cells and multiple myeloma, influencing cellular survival and response to therapy. Targeting USP8 reveals new opportunities for overcoming proteasome inhibitor resistance in multiple myeloma.
This study reveals that certain high-risk cytogenetic abnormalities continue to influence progression-free survival in multiple myeloma patients even after achieving deep MRD negativity post-ASCT, highlighting the need for tailored post-tra
